Semaglutide
- Generic Name
- Semaglutide
- Brand Names
- Ozempic, Rybelsus, Wegovy
- Drug Type
- Small Molecule
- Chemical Formula
- C187H291N45O59
- CAS Number
- 910463-68-2
- Unique Ingredient Identifier
- 53AXN4NNHX
- Background
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity. Other members of this drug class include Exenatide and Liraglutide. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. Th...
- Indication
Semaglutide is indicated to improve glycemic control in adults diagnosed with type 2 diabetes mellitus, and is used as an adjunct to diet and exercise. However, semaglutide is not a suitable first-line drug for diabetes that has not been controlled by diet and exercise. In addition, it has not been studied in patients with pancreatitis. Semaglutide is not in...
- Associated Conditions
- BMI >27 kg/m2, Cardiovascular Events, Obesity, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2018-10-03
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 304
- Registration Number
- NCT03693430
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Sevilla, Spain
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2274
- Registration Number
- NCT03689374
- Locations
- 🇹🇷
Novo Nordisk Investigational Site, Trabzon, Turkey
GLP1R in Parkinson's Disease
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Oslo University Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03659682
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)
- First Posted Date
- 2018-08-27
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 333
- Registration Number
- NCT03648281
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Örebro, Sweden
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice (SURE SWITZERLAND)
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 215
- Registration Number
- NCT03631186
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Zürich, Switzerland
Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program
- Conditions
- Interventions
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 611
- Registration Number
- NCT03611582
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Olympia, Washington, United States
A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese
- Conditions
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2021-11-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 96
- Registration Number
- NCT03600480
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Overland Park, Kansas, United States
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
- Conditions
- Interventions
- First Posted Date
- 2018-07-23
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1278
- Registration Number
- NCT03596450
- Locations
- 🇺🇸
Primary Care Research, Atlanta, Georgia, United States
🇺🇸Palm Research Center Inc-Vegas, Las Vegas, Nevada, United States
🇺🇸SC Clinical Research, Inc., Garden Grove, California, United States
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 17609
- Registration Number
- NCT03574597
- Locations
- 🇺🇸
Mercy Hospital and Medical Center, Chicago, Illinois, United States
🇺🇸Preferred Primary Care Physicians Inc., Pittsburgh, Pennsylvania, United States
🇺🇸Angel City Research, Inc., Los Angeles, California, United States
A Research Study of NNC0165-1562 and Semaglutide in People Who Are Overweight or Obese
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 37
- Registration Number
- NCT03574584
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Lincoln, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.